56,651 Shares in Pediatrix Medical Group, Inc. $MD Purchased by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG purchased a new stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 56,651 shares of the company's stock, valued at approximately $1,435,000. B. Metzler seel. Sohn & Co. AG owned about 0.07% of Pediatrix Medical Group at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MD. Global Retirement Partners LLC lifted its holdings in shares of Pediatrix Medical Group by 68,250.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company's stock valued at $29,000 after purchasing an additional 1,365 shares during the last quarter. Transamerica Financial Advisors LLC purchased a new position in shares of Pediatrix Medical Group during the 4th quarter valued at $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Pediatrix Medical Group during the 4th quarter worth about $33,000. TD Private Client Wealth LLC acquired a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at $39,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Pediatrix Medical Group in the fourth quarter worth about $43,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $26.59 on Monday. Pediatrix Medical Group, Inc. has a 12 month low of $15.69 and a 12 month high of $27.94. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of 12.72 and a beta of 0.66. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45. The stock has a 50-day moving average price of $25.77 and a 200 day moving average price of $22.98.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The company had revenue of $487.78 million during the quarter, compared to analyst estimates of $478.49 million. During the same period in the previous year, the company earned $0.53 EPS. The company's revenue for the quarter was up 4.1% compared to the same quarter last year. Research analysts expect that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group downgraded Pediatrix Medical Group from a "buy" rating to a "hold" rating and raised their price target for the company from $27.00 to $28.00 in a research report on Wednesday. Weiss Ratings raised shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a research note on Friday, May 8th. UBS Group lifted their price objective on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, August 6th. Finally, Truist Financial lifted their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a "hold" rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $25.00.

More Pediatrix Medical Group News

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Zacks increased its FY2026 EPS estimate to $2.11 from $2.02 and lifted its Q2 2027 forecast to $0.53 from $0.50. The firm also raised its FY2027 estimate to $2.10 from $1.94 and its FY2028 estimate to $2.04 from $1.88.
• Positive Sentiment: Quarterly estimates were raised for Q1 2027 to $0.37 from $0.34, Q3 2027 to $0.57 from $0.50, Q4 2027 to $0.63 from $0.59, and Q2 2028 to $0.49 from $0.43. These revisions suggest analysts see improving earnings potential beyond the current year.
• Positive Sentiment: Zacks also characterized MD as a strong momentum stock, which may attract additional buying from investors using quantitative or style-based strategies. Here's Why Pediatrix Medical Group Is a Strong Momentum Stock
• Neutral Sentiment: The current-year consensus EPS forecast remains $2.15, above Zacks’ revised $2.11 estimate for FY2026, indicating that the upgrades have not yet translated into a broader consensus increase.
• Negative Sentiment: Zacks lowered its Q1 2028 EPS forecast to $0.34 from $0.36, a relatively minor negative revision that partly offsets the broader pattern of upward estimate changes.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc NYSE: MD is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source